Origin and Function of Anti-Interferon Type I Viral Proteins
Virology,
Journal Year:
2025,
Volume and Issue:
605, P. 110456 - 110456
Published: Feb. 20, 2025
Language: Английский
Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions
Anzhelika Karjalainen,
No information about this author
Agnieszka Witalisz‐Siepracka,
No information about this author
Michaela Prchal‐Murphy
No information about this author
et al.
Cellular and Molecular Life Sciences,
Journal Year:
2025,
Volume and Issue:
82(1)
Published: March 2, 2025
Abstract
Tyrosine
kinase
2
(TYK2)
deficiency
and
loss
or
inhibition
of
activity
in
men
mice
leads
to
similar
immune
compromised
phenotypes,
predominantly
through
impairment
interferon
(IFN)
interleukin
12
family
responses.
Here
we
relate
the
transcriptome
changes
phenotypical
observed
TYK2-deficient
(
Tyk2
−/−
)
TYK2
kinase-inactive
K923E
naïve
splenic
cells
upon
ex
vivo
IFN
treatment
tumor
transplant
infiltration.
The
activities
under
homeostatic
both
challenged
conditions
are
highly
cell-type-specific
with
respect
quantity
quality
transcriptionally
dependent
genes.
major
impact
protein
macrophages,
NK
CD8
+
T
tumor-derived
cytolytic
is
on
While
reportedly
partial
IFN-I
responses,
identified
IFN-I-repressed
gene
sets
completely
activity.
Reported
functions
signaling
crosstalk,
metabolic
cell
differentiation
maturation.
None
these
phenotypes
relates
respective
enriched
types.
Nonetheless,
scaffolding
capable
change
transcriptional
at
single
levels
chromatin
accessibility
promoter-distal
regions
cytokine
most
prominently
cells.
transcriptomic
epigenetic
effects
shed
new
light
biology
this
JAK
member
relevant
for
current
future
autoimmune
inflammatory
diseases
inhibitors.
Language: Английский
Molecular mechanisms in DYT-PRKRA: pathways regulated by PKR activator protein PACT
Tricia A. Simon,
No information about this author
Rekha C. Patel
No information about this author
Dystonia,
Journal Year:
2025,
Volume and Issue:
4
Published: March 13, 2025
Dystonia-
PRKRA
(DYT-
),
previously
termed
dystonia
16
(DYT16),
is
a
movement
disorder
which
currently
has
very
limited
treatments
available
and
no
cure.
To
develop
effective
therapeutic
options,
it
essential
to
characterize
the
underlying
pathophysiology
identify
potential
drug
targets.
This
review
summarizes
recent
studies
that
shed
light
on
molecular
mechanisms
involved
in
DYT-
pathogenesis.
gene
encodes
for
protein
PACT
(Protein
Activator
of
Protein
Kinase
R)
individuals
with
mutations
early-onset
generalized
dystonia.
While
precise
linking
neuronal
etiology
remain
incompletely
understood,
research
indicates
such
cause
dysregulation
signaling
pathways
cellular
stress
response
as
well
production
antiviral
cytokines
interferons
(IFNs).
focuses
effect
known
functions
PACT.
Language: Английский